Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Harvard Business School
Medtronic
Express Scripts

Last Updated: August 19, 2022

Investigational Drug Information for Plinabulin


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Plinabulin?

Plinabulin is an investigational drug.

There have been 10 clinical trials for Plinabulin. The most recent clinical trial was a Phase 3 trial, which was initiated on May 29th 2018.

The most common disease conditions in clinical trials are Lung Neoplasms, Neutropenia, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are BeyondSpring Pharmaceuticals Inc., Lyudmila Bazhenova, M.D., and National Cancer Institute (NCI).

There are thirty-seven US patents protecting this investigational drug and two hundred and eighty-seven international patents.

Recent Clinical Trials for Plinabulin
TitleSponsorPhase
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)BeyondSpring Pharmaceuticals Inc.Phase 2
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)Memorial Sloan Kettering Cancer CenterPhase 2
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesM.D. Anderson Cancer CenterPhase 1/Phase 2

See all Plinabulin clinical trials

Clinical Trial Summary for Plinabulin

Top disease conditions for Plinabulin
Top clinical trial sponsors for Plinabulin

See all Plinabulin clinical trials

US Patents for Plinabulin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Plinabulin See Plans and Pricing Method of treating a brain tumor BeyondSpring Pharmaceuticals, Inc. (New York, NY) See Plans and Pricing
Plinabulin See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Plinabulin See Plans and Pricing Nanoparticle formulations for delivering multiple therapeutic agents AMRITA VISHWA VIDYAPEETHAM (Kochi, Kerala, unknown) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Harvard Business School
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.